Skip to main content
Top
Published in: Current Diabetes Reports 3/2013

01-06-2013 | Diabetes and Other Diseases—Emerging Associations (D Aron, Section Editor)

Diabetes and Infections-Hepatitis C: Is There Type 2 Diabetes Excess in Hepatitis C Infection?

Authors: Cho Naing, Joon Wah Mak, Nyunt Wai, Mala Maung

Published in: Current Diabetes Reports | Issue 3/2013

Login to get access

Abstract

Individual epidemiologic studies as well as the pooled analysis of observational studies have indicated the association between type 2 diabetes (T2D) and hepatitis C virus infection (HCV). Whether HCV infection is the cause of diabetes or diabetic patients are more prone to get HCV infection is still in question. The objective of the present review was to provide answers to this issue, based on available evidence from epidemiologic, molecular, experimental and therapeutic studies. Our current understanding of how chronic HCV infection could induce T2D is incomplete, but it seems twofold based on both direct and indirect roles of the virus. HCV may directly induce insulin resistance (IR) through its proteins. HCV core protein was shown to stimulate suppressor of cytokine signaling, resulting in ubiquitination and degradation of tyrosine kinase phosphorylated insulin receptor substrates (IRS1/2) in proteasomes. HCV-nonstructural protein could increase protein phosphatase 2A which has been shown to inactivate the key enzyme Akt by dephosphorylating it. Insulin signaling defects in hepatic IRS-1 tyrosine phosphorylation and PI3-kinase association/activation may contribute to IR, which leads to the development of T2D in patients with HCV infection. The peroxisome proliferator-activated receptors (PPARs) are also implicated. PPARα/γ, together with their obligate partner RXR, are the main nuclear receptors expressed in the liver. PPARα upregulates glycerol-3-phosphate dehydrogenase, glycerol kinase, and glycerol transport proteins, which allows for glucose synthesis during fasting states. Decreased activity of PPARs could attribute to HCV-induced IR. Immune-mediated mechanisms may be involved in the indirect role of HCV in inducing IR. It is speculated that TNF-alpha plays a major role in the pathogenesis of IR through lowering IRS1/2. Furthermore, HCV infection- triggered ER stress could lead to the activation of PP2A, which inhibits both Akt and the AMP-activated kinase, the regulators of gluconeogenesis. In summary, we illustrate that HCV infection is accompanied by multiple defects in the upstream insulin signaling pathway in the liver that may contribute to the observed prevalence of IR and diabetes. Future studies are needed to resolve this issue.
Literature
1.
go back to reference Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol. 1994;1135–9. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol. 1994;1135–9.
2.
go back to reference Alexander GJM. An association between hepatitis C virus and type 2 diabetes: what is the connection? Ann Intern Med. 2000;133:650–2.PubMedCrossRef Alexander GJM. An association between hepatitis C virus and type 2 diabetes: what is the connection? Ann Intern Med. 2000;133:650–2.PubMedCrossRef
3.
go back to reference Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;29:328–33.PubMedCrossRef Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;29:328–33.PubMedCrossRef
4.
go back to reference Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Hepatology. 2001;33:1554.PubMedCrossRef Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Hepatology. 2001;33:1554.PubMedCrossRef
5.
go back to reference Lecube A, Hernandez C, Genesca J, Simo R. Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis. Diabetes Care. 2006;29:1140–9.PubMedCrossRef Lecube A, Hernandez C, Genesca J, Simo R. Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis. Diabetes Care. 2006;29:1140–9.PubMedCrossRef
6.
go back to reference Mangia A, Schiavone G, Lezzi G, Marmo R, Bruno F, Villani MR, et al. HCV and diabetes mellitus: evidence for a negative association. Am J Gastroenterol. 1998;93:2363–7.PubMedCrossRef Mangia A, Schiavone G, Lezzi G, Marmo R, Bruno F, Villani MR, et al. HCV and diabetes mellitus: evidence for a negative association. Am J Gastroenterol. 1998;93:2363–7.PubMedCrossRef
7.
go back to reference Howard AA, Klein RS, Schoenbaum EE. Association of hepatitis C infection and antiretroviral use with diabetes mellitus in drug users. Clin Infect Dis. 2003;36:1318–23.PubMedCrossRef Howard AA, Klein RS, Schoenbaum EE. Association of hepatitis C infection and antiretroviral use with diabetes mellitus in drug users. Clin Infect Dis. 2003;36:1318–23.PubMedCrossRef
8.
go back to reference •• White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49:831–44. This systematic review, based on both prospective and retrospective studies, provided evidence on excess risk of T2D in HCV infection than in comparison with non-infected controls. Also, it was observed an excess risk in HICV infection than HBV infection, suggesting a potential direct viral role in promoting DM risk.PubMedCrossRef •• White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49:831–44. This systematic review, based on both prospective and retrospective studies, provided evidence on excess risk of T2D in HCV infection than in comparison with non-infected controls. Also, it was observed an excess risk in HICV infection than HBV infection, suggesting a potential direct viral role in promoting DM risk.PubMedCrossRef
9.
go back to reference •• Naing C, Mak JW, Ahmed SI, Maung M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol. 2012;18:1642–51. This meta- analysis of 17 observational studies assessing the relationship between HCV infection and T2D. The comparisons were done between HCV infected and not infected, and HCV infected and HBV infected. The findings support the association between HCV and T2D. However, the direction of association remains to be determined.PubMedCrossRef •• Naing C, Mak JW, Ahmed SI, Maung M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol. 2012;18:1642–51. This meta- analysis of 17 observational studies assessing the relationship between HCV infection and T2D. The comparisons were done between HCV infected and not infected, and HCV infected and HBV infected. The findings support the association between HCV and T2D. However, the direction of association remains to be determined.PubMedCrossRef
10.
go back to reference •• American Diabetes Association. Diagnosis and classification of Diabetes Mellitus. Diabetes Care. 2010;33 Suppl 1:S62–9. This document addresses comprehensive information on both etiologic classification and diagnostic criteria for diabetes mellitus.CrossRef •• American Diabetes Association. Diagnosis and classification of Diabetes Mellitus. Diabetes Care. 2010;33 Suppl 1:S62–9. This document addresses comprehensive information on both etiologic classification and diagnostic criteria for diabetes mellitus.CrossRef
11.
go back to reference • Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126:840–8. This article provides possible explanations between HCV and T2D based on animal model studies.PubMedCrossRef • Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126:840–8. This article provides possible explanations between HCV and T2D based on animal model studies.PubMedCrossRef
12.
go back to reference Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant. 2005;5(10):2433–40. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant. 2005;5(10):2433–40.
13.
go back to reference Wilkin TJ. The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia. 2001;44:914–22.PubMedCrossRef Wilkin TJ. The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia. 2001;44:914–22.PubMedCrossRef
14.
go back to reference Raj SM, Howson JM, Walker NM, Cooper JD, Smyth DJ, Field SF, et al. No association of multiple type 2 diabetes loci with type 1 diabetes. Diabetologia. 2009;52:2109–16.PubMedCrossRef Raj SM, Howson JM, Walker NM, Cooper JD, Smyth DJ, Field SF, et al. No association of multiple type 2 diabetes loci with type 1 diabetes. Diabetologia. 2009;52:2109–16.PubMedCrossRef
15.
go back to reference Verbeeten KC, Elks CE, Daneman D, Ong KK. Association between childhood obesity and subsequent type 1 diabetes: a systematic review and meta-analysis. Diabet Med. 2011;28:10–8.PubMedCrossRef Verbeeten KC, Elks CE, Daneman D, Ong KK. Association between childhood obesity and subsequent type 1 diabetes: a systematic review and meta-analysis. Diabet Med. 2011;28:10–8.PubMedCrossRef
17.
go back to reference McHutchison JG. Understanding hepatitis C. Am J Manag Care. 2004;10(Suppl):S21–9.PubMed McHutchison JG. Understanding hepatitis C. Am J Manag Care. 2004;10(Suppl):S21–9.PubMed
18.
go back to reference Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31:777–82.PubMedCrossRef Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31:777–82.PubMedCrossRef
19.
go back to reference Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–62.PubMedCrossRef Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–62.PubMedCrossRef
21.
go back to reference Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31:1090–101.PubMedCrossRef Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31:1090–101.PubMedCrossRef
22.
go back to reference Panlilio AL, Shapiro CN, Schable CA, Mendelson MH, Montecalvo MA, Kunches LM, et al. Serosurvey of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among hospital-based surgeons. Serosurvey Study Group. J Am Coll Surg. 1995;180:16–24.PubMed Panlilio AL, Shapiro CN, Schable CA, Mendelson MH, Montecalvo MA, Kunches LM, et al. Serosurvey of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among hospital-based surgeons. Serosurvey Study Group. J Am Coll Surg. 1995;180:16–24.PubMed
23.
go back to reference Gershon RR, Sherman M, Mitchell C, Vlahov D, Erwin MJ, Lears MK, et al. Prevalence and risk factors for blood borne exposure and infection in correctional healthcare workers. Infect Control Hosp Epidemiol. 2007;28:24–30.PubMedCrossRef Gershon RR, Sherman M, Mitchell C, Vlahov D, Erwin MJ, Lears MK, et al. Prevalence and risk factors for blood borne exposure and infection in correctional healthcare workers. Infect Control Hosp Epidemiol. 2007;28:24–30.PubMedCrossRef
24.
go back to reference Hall CS, Charlebois ED, Hahn JA, Moss AR, Bangsberg DR. Hepatitis C virus infection in San Francisco's HIV-infected urban poor. J Gen Intern Med. 2004;19:357–65.PubMedCrossRef Hall CS, Charlebois ED, Hahn JA, Moss AR, Bangsberg DR. Hepatitis C virus infection in San Francisco's HIV-infected urban poor. J Gen Intern Med. 2004;19:357–65.PubMedCrossRef
25.
go back to reference Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000;133:592–9.PubMedCrossRef Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000;133:592–9.PubMedCrossRef
26.
go back to reference Imazeki F, Yokosuka O, Fukai K, Kanda T, Kojima H, Saisho H. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients. Liver Int. 2008;28:355–62.PubMedCrossRef Imazeki F, Yokosuka O, Fukai K, Kanda T, Kojima H, Saisho H. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients. Liver Int. 2008;28:355–62.PubMedCrossRef
27.
go back to reference • Balbi M, Donadon V, Ghersetti M, et al. Alcohol and HCV chronic infection are risk cofactors of type 2 diabetes mellitus for hepatocellular carcinoma in Italy. Int J Environ Res Public Health. 2010;7:1366–78. This is a retrospective, case-control study with 465 consecutive patients with HCC, assessing the effect of alcohol consumption and HCV infections alone and as co-factors of diabetes mellitus, on the risk of HCC in Italian patients. Interestingly, this study examined whether the combined effect of 2 factors on HCC was greater than the sum of the individual effects, using the Rothman’s synergy index method.PubMedCrossRef • Balbi M, Donadon V, Ghersetti M, et al. Alcohol and HCV chronic infection are risk cofactors of type 2 diabetes mellitus for hepatocellular carcinoma in Italy. Int J Environ Res Public Health. 2010;7:1366–78. This is a retrospective, case-control study with 465 consecutive patients with HCC, assessing the effect of alcohol consumption and HCV infections alone and as co-factors of diabetes mellitus, on the risk of HCC in Italian patients. Interestingly, this study examined whether the combined effect of 2 factors on HCC was greater than the sum of the individual effects, using the Rothman’s synergy index method.PubMedCrossRef
28.
go back to reference Qureshi H, Ahsan T, Mujeeb SA, Jawad F, Mehdi I, Ahmed W, et al. Diabetes mellitus is equally frequent in chronic HCV and HBV infection. J Pak Med Assoc. 2002;52:280–3.PubMed Qureshi H, Ahsan T, Mujeeb SA, Jawad F, Mehdi I, Ahmed W, et al. Diabetes mellitus is equally frequent in chronic HCV and HBV infection. J Pak Med Assoc. 2002;52:280–3.PubMed
29.
30.
go back to reference Antonelli A, Ferri C, Fallahi P, Sebastiani M, Nesti C, Barani L, et al. Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients. Rheumatology. 2004;43:238–40.PubMedCrossRef Antonelli A, Ferri C, Fallahi P, Sebastiani M, Nesti C, Barani L, et al. Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients. Rheumatology. 2004;43:238–40.PubMedCrossRef
31.
go back to reference Chehadeh W, Abdella N, Ben-Nakhi A, Al-Arouj M, Al-Nakib W. Risk factors for the development of diabetes mellitus in chronic hepatitis C virus genotype 4 infection. J Gastroenterol Hepatol. 2009;24:42–8.PubMedCrossRef Chehadeh W, Abdella N, Ben-Nakhi A, Al-Arouj M, Al-Nakib W. Risk factors for the development of diabetes mellitus in chronic hepatitis C virus genotype 4 infection. J Gastroenterol Hepatol. 2009;24:42–8.PubMedCrossRef
32.
go back to reference White MF, Shoelson SE, Keutmann H, Kahn CR. A cascade of tyrosine autophosphorylation in the beta-subunit activates the insulin receptor. J Biol Chem. 1988;263:2969–80.PubMed White MF, Shoelson SE, Keutmann H, Kahn CR. A cascade of tyrosine autophosphorylation in the beta-subunit activates the insulin receptor. J Biol Chem. 1988;263:2969–80.PubMed
33.
go back to reference Kappel CR, Kretzmann NA, Alvares-da-Silva MR. IRS-1 expression in hepatic tissue and leukocytes in chronic hepatitis C virus infected patients: a comparative study. Int J Hepatol. 2012;2012:698905. doi:10.1155/2012/698905.PubMed Kappel CR, Kretzmann NA, Alvares-da-Silva MR. IRS-1 expression in hepatic tissue and leukocytes in chronic hepatitis C virus infected patients: a comparative study. Int J Hepatol. 2012;2012:698905. doi:10.​1155/​2012/​698905.PubMed
34.
go back to reference •• Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling. Am J Pathol. 2004;165:1499–508. This article addressed an empirical study reporting the presence of severe insulin resistance in noncirrhotic patients with HCV infection more than in patients with other hepatobiliary diseases.PubMedCrossRef •• Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling. Am J Pathol. 2004;165:1499–508. This article addressed an empirical study reporting the presence of severe insulin resistance in noncirrhotic patients with HCV infection more than in patients with other hepatobiliary diseases.PubMedCrossRef
35.
go back to reference Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol. 2007;102:570–6.PubMedCrossRef Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol. 2007;102:570–6.PubMedCrossRef
36.
go back to reference Bernsmeier C, Duong FH, Christen V, Pugnale P, Negro F, Terracciano L, et al. Virus-induced over-expression of protein phosphatase 2A inhibits insulin signaling in chronic hepatitis C. J Hepatol. 2008;49:429–40.PubMedCrossRef Bernsmeier C, Duong FH, Christen V, Pugnale P, Negro F, Terracciano L, et al. Virus-induced over-expression of protein phosphatase 2A inhibits insulin signaling in chronic hepatitis C. J Hepatol. 2008;49:429–40.PubMedCrossRef
37.
go back to reference •• Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI-3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology. 2003;38:1384–92. This study examined the molecular basis of IR in HCV and. documented the impact of HCV infection on early steps of insulin signaling cascade, the association of IR with IRS -1 , and its impact on the upstream insulin signaling components such as PI 3 -kinase and Akt in liver biopsy specimens obtained from 42 nondiabetic HCV-infected patients. •• Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI-3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology. 2003;38:1384–92. This study examined the molecular basis of IR in HCV and. documented the impact of HCV infection on early steps of insulin signaling cascade, the association of IR with IRS -1 , and its impact on the upstream insulin signaling components such as PI 3 -kinase and Akt in liver biopsy specimens obtained from 42 nondiabetic HCV-infected patients.
38.
39.
go back to reference Bardot O, Aldridge TC, Latruffe N, Green S. PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene. Biochem Biophys Res Commun. 1993;192:37–45.PubMedCrossRef Bardot O, Aldridge TC, Latruffe N, Green S. PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene. Biochem Biophys Res Commun. 1993;192:37–45.PubMedCrossRef
40.
go back to reference • Eslam M, Khattab MA, Harrison SA. Peroxisome proliferator-activated receptors and hepatitis C virus. Ther Adv Gastroenterol. 2011;4:419–31. This review article explained the details about the role of PPARs in glucose homeostasis.CrossRef • Eslam M, Khattab MA, Harrison SA. Peroxisome proliferator-activated receptors and hepatitis C virus. Ther Adv Gastroenterol. 2011;4:419–31. This review article explained the details about the role of PPARs in glucose homeostasis.CrossRef
41.
go back to reference Patsouris D, Mandard S, Voshol PJ, et al. PPARα governs glycerol metabolism. J Clin Invest. 2004;114:94–103.PubMed Patsouris D, Mandard S, Voshol PJ, et al. PPARα governs glycerol metabolism. J Clin Invest. 2004;114:94–103.PubMed
42.
go back to reference Jiang G, Dallas-Yang Q, Li Z, Szalkowski D, Liu F, Shen X, et al. Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPAR gamma agonists. Diabetes. 2002;51:2412–9.PubMedCrossRef Jiang G, Dallas-Yang Q, Li Z, Szalkowski D, Liu F, Shen X, et al. Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPAR gamma agonists. Diabetes. 2002;51:2412–9.PubMedCrossRef
43.
go back to reference Dharancy S, Malapel M, Perlemuter G, et al. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology. 2005;128:334–42.PubMedCrossRef Dharancy S, Malapel M, Perlemuter G, et al. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology. 2005;128:334–42.PubMedCrossRef
44.
go back to reference de Gottardi A, Pazienza V, Pugnale P, Bruttin F, Rubbia-Brandt L, Juge-Aubry CE, et al. Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Aliment Pharmacol Ther. 2006;23:107–14.PubMedCrossRef de Gottardi A, Pazienza V, Pugnale P, Bruttin F, Rubbia-Brandt L, Juge-Aubry CE, et al. Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Aliment Pharmacol Ther. 2006;23:107–14.PubMedCrossRef
45.
go back to reference Clément S, Pascarella S, Negro F. Hepatitis C virus infection: molecular pathways to steatosis, insulin resistance, and oxidative stress. Viruses. 2009;1:126–43.PubMedCrossRef Clément S, Pascarella S, Negro F. Hepatitis C virus infection: molecular pathways to steatosis, insulin resistance, and oxidative stress. Viruses. 2009;1:126–43.PubMedCrossRef
46.
go back to reference Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126:840–8. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126:840–8.
47.
go back to reference Kmieć Z. Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol. 2001;161:1–151.CrossRef Kmieć Z. Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol. 2001;161:1–151.CrossRef
48.
go back to reference Costantini S, Castello G, Colonna G. Human cytokinome: a new challenge for systems biology. Bioinformation. 2010;5:166–7.PubMedCrossRef Costantini S, Castello G, Colonna G. Human cytokinome: a new challenge for systems biology. Bioinformation. 2010;5:166–7.PubMedCrossRef
49.
go back to reference •• Costantini S, Capone F, Guerriero E, Marfella R, Sorice A, Maio P, et al. Cytokinome profile of patients with type 2 diabetes and/or chronic hepatitis C infection. PLoS One. 2012;7:e39486. This is a primary study assessing comparative profile of cytokines in patients with T2D, chronic hepatitis C, chronic hepatitis C related T2D, or chronic hepatitis C related cirrhosis, and healthy control subjects. This article reported specific markers for the different disease staging.PubMedCrossRef •• Costantini S, Capone F, Guerriero E, Marfella R, Sorice A, Maio P, et al. Cytokinome profile of patients with type 2 diabetes and/or chronic hepatitis C infection. PLoS One. 2012;7:e39486. This is a primary study assessing comparative profile of cytokines in patients with T2D, chronic hepatitis C, chronic hepatitis C related T2D, or chronic hepatitis C related cirrhosis, and healthy control subjects. This article reported specific markers for the different disease staging.PubMedCrossRef
51.
go back to reference Zekri ARN, Ashour MSE, Hassan A, Alam El-Din MA, El-Shehaby AMR, Abu-Shady MA. Cytokine profile in Egyptian HCV genotype-4 in relation to liver disease progression. World J Gastroenterol. 2005;11:6624–30.PubMed Zekri ARN, Ashour MSE, Hassan A, Alam El-Din MA, El-Shehaby AMR, Abu-Shady MA. Cytokine profile in Egyptian HCV genotype-4 in relation to liver disease progression. World J Gastroenterol. 2005;11:6624–30.PubMed
52.
go back to reference Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance, and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest. 2002;(Suppl 3):24–34. Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance, and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest. 2002;(Suppl 3):24–34.
53.
go back to reference Hotamisligil GS. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes. 2005;(Suppl 2):S73–8. Hotamisligil GS. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes. 2005;(Suppl 2):S73–8.
54.
go back to reference Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004;306:457–61.PubMedCrossRef Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004;306:457–61.PubMedCrossRef
55.
go back to reference Christen V, Treves S, Duong FH, Heim MH. Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A. Hepatology. 2007;46:558–65.PubMedCrossRef Christen V, Treves S, Duong FH, Heim MH. Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A. Hepatology. 2007;46:558–65.PubMedCrossRef
56.
go back to reference Romero-Gómez M, Del Mar VM, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636–41.PubMedCrossRef Romero-Gómez M, Del Mar VM, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636–41.PubMedCrossRef
57.
go back to reference Romero-Gómez M, Fernández-Rodríguez CM, Andrade RJ, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol. 2008;48:721–7.PubMedCrossRef Romero-Gómez M, Fernández-Rodríguez CM, Andrade RJ, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol. 2008;48:721–7.PubMedCrossRef
58.
go back to reference Dai CY, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol. 2009;50:712–8.PubMedCrossRef Dai CY, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol. 2009;50:712–8.PubMedCrossRef
59.
go back to reference Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol. 2008;48:28–34.PubMedCrossRef Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol. 2008;48:28–34.PubMedCrossRef
60.
go back to reference Khattab M, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol. 2010;105:1970–7.PubMedCrossRef Khattab M, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol. 2010;105:1970–7.PubMedCrossRef
Metadata
Title
Diabetes and Infections-Hepatitis C: Is There Type 2 Diabetes Excess in Hepatitis C Infection?
Authors
Cho Naing
Joon Wah Mak
Nyunt Wai
Mala Maung
Publication date
01-06-2013
Publisher
Current Science Inc.
Published in
Current Diabetes Reports / Issue 3/2013
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-013-0370-3

Other articles of this Issue 3/2013

Current Diabetes Reports 3/2013 Go to the issue

Macrovascular Complications in Diabetes (PD Reaven, Section Editor)

Vascular Calcification in Diabetes: Mechanisms and Implications

Macrovascular Complications in Diabetes (PD Reaven, Section Editor)

Is the Risk and Nature of CVD the Same in Type 1 and Type 2 Diabetes?

Macrovascular Complications in Diabetes (PD Reaven, Section Editor)

Do Statins Cause Diabetes?

Diabetes and Other Diseases—Emerging Associations (D Aron, Section Editor)

Diabetes Mellitus and Periodontal Diseases

Diabetes and Other Diseases—Emerging Associations (D Aron, Section Editor)

Diabetes Mellitus and Inflammation

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.